{
  "id": 20980995,
  "title": "Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial",
  "url": "https://urgent.news/2026/11/21/capricors-duchenne-therapy-is-rejected-again-as-fda-cites-significant",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-21T01:11:10.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/capricors-duchenne-therapy-is-rejected-again-as-fda-cites-significant-issues-with-trial/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Capricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In a",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming",
        "url": "https://urgent.news/2026/11/20/stat-fda-rejects-capricor-therapeutics-duchenne-therapy-a-decision",
        "published": "2026-11-20T23:43:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}